Insider Buying Fuels Confidence in Scholar Rock’s Cell‑and‑Gene Therapy Pipeline
Insider buying spikes at Scholar Rock (SRHC) as insiders bet on 2026 FDA approvals and a shift from negative to positive earnings, boosting investor confidence.
5 minutes to read